This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

28/100

✓ Peer-reviewed alzhub usefulness score 28 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Alzheimer's disease, AD, has been a difficult problem for relevant experts and patients since its discovery. As a neurodegenerative disease, it can lead to cognitive decline and seriously affect the patient's life. In recent years, with the aging of the world's population, and the combination of various factors, the prevalence of Alzheimer's disease worldwide has been increasing, causing widespread concern in society. The pathogenesis of Alzheimer's disease is complex, which is one of the reasons why it is difficult to find an effective treatment until now. Extracellular plaques and intracellular tangles are more important causes of disease. They block communication between nerve cells and cause the death of nerve cells. It makes the patient's brain atrophy, neuroplasticity decline, and ultimately more severe cognitive decline. Most of the current treatments for Alzheimer's disease point to the formation path of plaques and tangles. There are also monoclonal antibody drugs that are more directly directed against plaques. However, almost all of these drugs have disadvantages such as insufficient efficacy or more serious side effects. Most of the drugs used to treat AD can only relieve pathological processes such as cognitive decline in patients, and there is a lack of treatment for patients with more severe symptoms. Most of the current research has been carried out from both pathogenesis and drug development. This article will also review the progress of AD and related research from these two aspects, respectively.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Cheng, Z. (2025). Alzheimer disease: Mechanism and treatments. Theoretical and Natural Science. https://doi.org/10.54254/2753-8818/2024.la19840

Vancouver

Cheng Z. Alzheimer disease: Mechanism and treatments. Theoretical and Natural Science. 2025. doi:10.54254/2753-8818/2024.la19840.

BibTeX

@article{cheng2025-0fda535b,
  author  = {Cheng, Zonghao},
  title   = {{Alzheimer disease: Mechanism and treatments}},
  journal = {Theoretical and Natural Science},
  year    = {2025},
  doi     = {10.54254/2753-8818/2024.la19840},
  url     = {https://doi.org/10.54254/2753-8818/2024.la19840}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

There are also monoclonal antibody drugs that are more directly directed against plaques.
However, almost all of these drugs have disadvantages such as insufficient efficacy or more serious side effects.
Most of the drugs used to treat AD can only relieve pathological processes such as cognitive decline in patients, and there is a lack of treatment for patients with more severe symptoms.
Most of the current research has been carried out from both pathogenesis and drug development.
This article will also review the progress of AD and related research from these two aspects, respectively.

Why it matters

This review describes how amyloid plaques and tau tangles are important causes of Alzheimer disease and notes that most current treatments only relieve cognitive decline, while monoclonal antibody drugs against plaques have drawbacks such as insufficient efficacy or serious side effects. It concludes there is still a lack of treatment for patients with more severe symptoms.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Evidence strengthLow

How this study scored 28/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 27 of the 96 points we could judge it on, which is 28 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Theoretical and Natural Science)
Journal's citation record	0 / 4	Theoretical and Natural Science: journal h-index 10 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 1 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.3 citations a year over 3 year(s) since 2025
Impact for its field and year	1 / 6	Cited 0.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	Senior author's record not available — left out of this score
Institution's track record	0 / 3	Beijing Forestry University: institution h-index 334 (OpenAlex)
Multi-centre collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	1 / 2	Not in PubMed, but has a DOI
Free to read	2 / 2	Free to read
Points	27 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 27 of the 96 points we could judge it on is 28 out of 100.
Total	28 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Treatments

Also in Treatments

197 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →